In sequence, Hong et al. reported clinical and laboratory findings from patients with CD19-R/R ALL after receiving CAR-T cell therapy, aiming to identify modifications in endothelial activation-related molecules that could be characterized as biomarkers associated with CRS [50]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.